Product Description
Mechanisms of Action: 5-HT2A Binder
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hospices Civils de Lyon
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Tourette Syndrome|Rett Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
69HCL22_0683 | P2 |
Unknown Status |
Tourette Syndrome|Rett Syndrome |
2028-10-01 |
|
2019-000340-99 | P2 |
Completed |
Unknown |
2023-04-26 |
|
Park-IMPULSE | N/A |
Unknown status |
Conduct Disorder|Parkinson's Disease |
2022-02-13 |